---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-096047"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:33:21.275257+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rigel licenses olutasidenib to Kissei for Japan, Korea, Taiwan; $10M upfront + up to $152.5M milestones

## Summary
- Rigel receives $10M upfront; eligible for up to $152.5M in development, regulatory, and commercial milestones.
- Mid-twenties to low-thirties percent tiered royalty on net sales; Kissei funds all development in territory.
- Forma Therapeutics (Novo Nordisk) owed $2.3M from the upfront payment under prior sublicense.
- Rigel retains global rights outside Japan, Korea, Taiwan; supplies bulk drug product under separate agreement.
- Kissei responsible for companion diagnostic costs in Japan; Rigel shares 50% up to $3M, creditable against milestones.

## SEC filing metadata
- accession: 0001104659-24-096047
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465924096047/0001104659-24-096047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465924096047/tm2423224d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-096047
- JSON: https://secwatch.observer/filing/0001104659-24-096047.json
- Plain text: https://secwatch.observer/filing/0001104659-24-096047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.